Report of Foreign Issuer (6-k)
November 29 2016 - 4:35PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of
1934
For the Month of November 2016
001-37353
(Commission File Number)
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of Registrant as specified
in its charter)
14 Einstein St.
Ness Ziona
Israel 74036
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
____
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If "Yes" is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
On November 29, 2016, Biondvax Pharmaceuticals Ltd.
("BiondVax") issued a press release announcing its positive preliminary safety results from its European Phase 2b clinical
trial of M-001, its universal flu vaccine candidate. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated November 29, 2016
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: November 29, 2016
|
By:
|
/s/ Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
3
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024